Skip to content

Famotidine

FDA-approved product (tablet, oral), marketed as Famotidine, Famotidine Preservative Free, Famotidine Preservative Free (Pharmacy Bulk) and 7 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Famotidine
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Chest pain
  • Duodenal ulcer
  • Dyspepsia
  • Esophagitis
  • Gastric ulcer
  • Gastroesophageal reflux disease
  • Osteoarthritis
  • Peptic ulcer
  • Rheumatoid arthritis
  • Ulcer disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
H2-receptor antagonists
FDA pharmacologic class
Histamine-2 Receptor Antagonist FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA29.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli28.3% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae20.9% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis57.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-5.7 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.2 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-6.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.0 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Famotidine with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Stress Ulcer Prophylaxis Versus Placebo in Critically Ill Infants With Congenital Heart Disease

    NCT03667703 · start 2019-03-10

    Registered record
    Registry ID
    NCT03667703
    Conditions
    Congenital Heart Disease; Upper Gastrointestinal Bleeding; Stress Ulcer; Infection
    Interventions
    Famotidine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2019-03-10
    Completion
    2022-06-30
    Enrolment
    70

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Heart Disease; Upper Gastrointestinal Bleeding; Stress Ulcer; Infection
    InterventionFamotidine; Placebo
    PhasePhase 4
    Registry statusCompleted
  • Study to Assess the Pharmacokinetic Drug-Drug Interactions of Lemborexant When Coadministered With an Oral Contraceptive, Famotidine, or Fluconazole in Healthy Subjects

    NCT03451110 · start 2018-02-05

    Registered record
    Registry ID
    NCT03451110
    Conditions
    Healthy Subjects
    Interventions
    lemborexant; Loestrin; famotidine; fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2018-02-05
    Completion
    2018-03-23
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    Interventionlemborexant; Loestrin; famotidine; fluconazole
    PhasePhase 1
    Registry statusCompleted
  • IONSYS Feasibility Study

    NCT03021083 · start 2017-11-01

    Registered record
    Registry ID
    NCT03021083
    Conditions
    Spinal Injury
    Interventions
    IONSYS Patch
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Withdrawn
    Start
    2017-11-01
    Completion
    2017-11-01
    Enrolment
    0

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSpinal Injury
    InterventionIONSYS Patch
    PhasePhase 4
    Registry statusWithdrawn
  • A Phase 1 Study to Evaluate the Effects of Omeprazole and Famotidine on the Absorption of Telotristat Ethyl in Healthy Subjects

    NCT03302845 · start 2017-09-21

    Registered record
    Registry ID
    NCT03302845
    Conditions
    Drug-drug Interaction
    Interventions
    Omeprazole 40 MG; Famotidine 40 mg; Telotristat ethyl 250 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2017-09-21
    Completion
    2017-11-07
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDrug-drug Interaction
    InterventionOmeprazole 40 MG; Famotidine 40 mg; Telotristat ethyl 250 mg
    PhasePhase 1
    Registry statusCompleted
  • Chemotherapy and Locoregional Therapy Trial (Surgery or Radiation) for Patients With Head and Neck Cancer

    NCT03107182 · start 2017-06-27

    Registered record
    Registry ID
    NCT03107182
    Conditions
    HPV-Related Squamous Cell Carcinoma; HNSCC
    Interventions
    nab-paclitaxel; Carboplatin; Nivolumab; Cisplatin; Hydroxyurea; 5-FU; Dexamethasone; Famotidine; Diphenhydramine; Paclitaxel; Transoral robotic surgery (TORS); Adjuvant RT; Chemoradiotherapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-06-27
    Completion
    2024-09-06
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHPV-Related Squamous Cell Carcinoma; HNSCC
    Interventionnab-paclitaxel; Carboplatin; Nivolumab; Cisplatin +9 more
    PhasePhase 2
    Registry statusCompleted
  • A Study to Examine the Effect of Omeprazole, Famotidine, and an Acidic Beverage on the Pharmacokinetics of Entinostat in Healthy Adult Subjects

    NCT02922933 · start 2016-10-25

    Registered record
    Registry ID
    NCT02922933
    Conditions
    Volunteers; Healthy Volunteers; Human Volunteers; Normal Volunteers
    Interventions
    entinostat; Omeprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-10-25
    Completion
    2017-05-08
    Enrolment
    66

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVolunteers; Healthy Volunteers; Human Volunteers; Normal Volunteers
    Interventionentinostat; Omeprazole; Famotidine
    PhasePhase 1
    Registry statusCompleted
  • Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

    NCT02684799 · start 2016-01-31

    Registered record
    Registry ID
    NCT02684799
    Conditions
    Healthy
    Interventions
    Cenicriviroc; Omeprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-31
    Completion
    2016-04-11
    Enrolment
    48

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionCenicriviroc; Omeprazole; Famotidine
    PhasePhase 1
    Registry statusCompleted
  • A Study to Assess the Effect of High Fat Meal and Increased Gastric pH on the Bioavailability of an Extended Release Formulation of BMS-663068 in Healthy Subjects

    NCT02666053 · start 2016-01-27

    Registered record
    Registry ID
    NCT02666053
    Conditions
    Infection, Human Immunodeficiency Virus
    Interventions
    BMS-663068
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-01-27
    Completion
    2016-02-22
    Enrolment
    72

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus
    InterventionBMS-663068
    PhasePhase 1
    Registry statusCompleted
  • Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis

    NCT02534636 · start 2015-10

    Registered record
    Registry ID
    NCT02534636
    Conditions
    Healthy Subjects
    Interventions
    BMS-986165; Interferon alpha-2a recombinant; Famotidine; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10
    Completion
    2016-11
    Enrolment
    140

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Subjects
    InterventionBMS-986165; Interferon alpha-2a recombinant; Famotidine; Placebo
    PhasePhase 1
    Registry statusCompleted
  • Anesthetics in Rhytidoplasty - A Comparison Study

    NCT02410460 · start 2013-09

    Registered record
    Registry ID
    NCT02410460
    Conditions
    Rhytidoplasty
    Interventions
    clonidine; glycopyrrolate; propofol; ketamine; marcaine; scopolamine; midazolam; ondansetron; metoclopramide; glycopyrrolate; lidocaine; famotidine; desflurane; sevoflurane
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2013-09
    Completion
    2014-06
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRhytidoplasty
    Interventionclonidine; glycopyrrolate; propofol; ketamine +10 more
    PhaseNot applicable
    Registry statusCompleted
  • Proton Pump Inhibitor Versus Histamine-2 Receptor Antagonist for the Prevention of Recurrent Peptic Ulcers

    NCT02551744 · start 2012-07

    Registered record
    Registry ID
    NCT02551744
    Conditions
    Peptic Ulcer
    Interventions
    histamine-2 receptor antagonist group; proton pump inhibitor group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2012-07
    Completion
    2018-07
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPeptic Ulcer
    Interventionhistamine-2 receptor antagonist group; proton pump inhibitor group
    PhaseNot applicable
    Registry statusCompleted
  • Open-label Safety and Pharmacokinetic Study of DUEXIS® (Ibuprofen and Famotidine) Tablets in Juvenile Idiopathic Arthritis

    NCT01563185 · start 2012-04

    Registered record
    Registry ID
    NCT01563185
    Conditions
    Juvenile Idiopathic Arthritis
    Interventions
    800 mg ibuprofen/26.6 mg famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2012-04
    Completion
    2015-03
    Enrolment
    12

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionJuvenile Idiopathic Arthritis
    Intervention800 mg ibuprofen/26.6 mg famotidine
    PhasePhase 4
    Registry statusCompleted
  • Famotidine for Levodopa-induced Dyskinesia in PD

    NCT01937078 · start 2011-04

    Registered record
    Registry ID
    NCT01937078
    Conditions
    Dyskinesia
    Interventions
    Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-04
    Completion
    2014-03
    Enrolment
    7

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDyskinesia
    InterventionFamotidine
    PhasePhase 2
    Registry statusCompleted
  • Influence of Esomeprazole on Antiplatelet Action of Clopidogrel Associated With Aspirin

    NCT01062516 · start 2010-01

    Registered record
    Registry ID
    NCT01062516
    Conditions
    Acute Coronary Syndrome; Acute Myocardial Infarction
    Interventions
    esomeprazole 20 mg daily; famotidine 40 mg daily
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2010-01
    Completion
    2010-09
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Coronary Syndrome; Acute Myocardial Infarction
    Interventionesomeprazole 20 mg daily; famotidine 40 mg daily
    PhasePhase 4
    Registry statusCompleted
  • Esomeprazole or Famotidine in the Management of Aspirin Related Non-Ulcer Dyspepsia

    NCT00978159 · start 2009-09

    Registered record
    Registry ID
    NCT00978159
    Conditions
    Aspirin; Dyspepsia
    Interventions
    esomeprazole; Famotidine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2009-09
    Completion
    2013-12
    Enrolment
    128

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAspirin; Dyspepsia
    Interventionesomeprazole; Famotidine
    PhasePhase 4
    Registry statusUnknown